


Palonosetron

Cat. No.:	HY-A0018
CAS No.:	135729-61-2
Molecular Formula:	C ₁₉ H ₂₄ N ₂ O
Molecular Weight:	296.41
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Palonosetron is a 5-HT ₃ antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). IC ₅₀ Value: Target: 5-HT ₃ Receptor Palonosetron is the most effective of the 5-HT ₃ antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy.
IC₅₀ & Target	5-HT ₃ Receptor

CUSTOMER VALIDATION

- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Celio L, Agustoni F, Testa I, Dotti K, De Braud F. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. *Tumori*. 2012 May;98(3):279-86.
- [2]. Blazer M, Phillips G, Reardon J, Efries D, Smith Y, Weatherby L, Juergens K, Rose J, Griffith N, Bekaii-Saab T. Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. *Oncology*. 2012;83(3):135-40. Epub 2012 Jul 18.
- [3]. Dogan U, Yavas G, Tekinalp M, Yavas C, Ata OY, Ozdemir K. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization. *Eur Rev Med Pharmacol Sci*. 2012 Apr;16(4):462-8.
- [4]. Jin Y, Sun W, Gu D, Yang J, Xu Z, Chen J. Comparative efficacy and safety of palonosetron with the first 5-HT₃ receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis. *Eur J Cancer Care (Engl)*. 2012 Apr 22.
- [5]. Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglén, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al. 2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT₃ receptor antagonists. *J. Med. Chem.*, 1993, 36 (18), pp 2645-2657

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA